Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

How not to read an EEG
Tatum, William O.

Neurology | December 24, 2012 | Volume: 80 | Issue: 1_supplement_1 | Pages: No page available

10.1212/wnl.0b013e318279730e | PMID 23267040 Get It

ANNA‐1 (anti‐Hu) associated sensory neuronopathy with malignant mixed mullerian tumor
Fournier, Christina , Kalra, Aarti, Zarwan, Corinne, Srinivasan, Jayashri, Lachance, Daniel Honore

Muscle & Nerve | December 24, 2012 | Volume: 47 | Issue: 5 | Pages: 776-777

10.1002/mus.23764 | PMID 23536385 Get It

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
Castellano, Daniel , Bajetta, Emilio, Panneerselvam, Ashok, Saletan, Stephen, Kocha, Walter, O’Dorisio, Thomas M. , Anthony, Lowell , Hobday, Timothy J. , Group, RADIANT-2 Study, Group, RADIANT-2 Study

The Oncologist | December 23, 2012 | Volume: 18 | Issue: 1 | Pages: 46-53

10.1634/theoncologist.2012-0263 | PMID 23263288 Get It

AbstractIntroduction.The incidence of colorectal neuroendocrine tumors (NETs) is increasing, and patients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade.Methods.A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression-free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed.Results.Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n = 19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95% confidence interval: 0.13–0.89; p = .011). Although no objective responses were observed, tumor shrinkage was more frequently noted in the everolimus plus octreotide LAR arm than in the placebo plus octreotide LAR arm (67% vs. 37%, respectively). The combination of everolimus plus octreotide LAR was generally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events.Conclusions.Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.
The mystery of a crimson leg: A case of Klippel–Trénaunay–Weber syndrome
Geske, Jeffrey B. , Jouni, Hayan, Hoyt, John R., Geske, Jeffrey B

Vascular Medicine | December 22, 2012 | Volume: 18 | Issue: 1 | Pages: 49-50

10.1177/1358863x12468937 | PMID 23263154 Get It

Metformin and risk of hepatocellular carcinoma: are statins the missing link?
Singh, Siddharth , Singh, Preet Paul

Gut | December 22, 2012 | Volume: 62 | Issue: 6 | Pages: 951-952

10.1136/gutjnl-2012-304232 | PMID 23263525 Get It

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
Keaveny, Tony M. , Kopperdahl, David L. , Wermers, Robert A. , Wan, Xiaohai, Krohn, Kelly, Krege, John H. , Cosman, Felicia

Journal of Bone and Mineral Research | December 22, 2012 | Volume: 28 | Issue: 6 | Pages: 1328-1336

10.1002/jbmr.1853 | PMID 23281041 Get It

ABSTRACT Many postmenopausal women treated with teriparatide for osteoporosis have previously received antiresorptive therapy. In women treated with alendronate (ALN) or raloxifene (RLX), adding versus switching to teriparatide produced different responses in areal bone mineral density (aBMD) and biochemistry; the effects of these approaches on volumetric BMD (vBMD) and bone strength are unknown. In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day. Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis. A statistical plan specifying analyses was approved before assessments were completed. At the spine, median vBMD and strength increased from baseline in all groups (13.2% to 17.5%, p < 0.01); there were no significant differences between the Add and Switch groups. In the RLX stratum, hip vBMD and strength increased at 6 and 18 months in the Add group but only at 18 months in the Switch group (Strength, Month 18: 2.7% Add group, p < 0.01 and 3.4% Switch group, p < 0.05). In the ALN stratum, hip vBMD increased in the Add but not in the Switch group (0.9% versus –0.5% at 6 months and 2.2% versus 0.0% at 18 months, both p ≤ 0.004 group difference). At 18 months, hip strength increased in the Add group (2.7%, p < 0.01) but not in the Switch group (0%); however, the difference between groups was not significant (p = 0.076). Adding or switching to teriparatide conferred similar benefits on spine strength in postmenopausal women with osteoporosis pretreated with ALN or RLX. Increases in hip strength were more variable. In RLX-treated women, strength increased more quickly in the Add group; in ALN-treated women, a significant increase in strength compared with baseline was seen only in the Add group.
Intrinsic microvasculature of the sciatic nerve in the rat
Zamir, M. , Twynstra, Jasna , Vercnocke, Andrew J. , Welch, Ian, Jorgensen, Steve M., Ritman, Erik L., Holdsworth, David W. , Shoemaker, J. Kevin , Jorgensen, Steven M., Shoemaker, J Kevin

Journal of the Peripheral Nervous System | December 22, 2012 | Volume: 17 | Issue: 4 | Pages: 377-384

10.1111/j.1529-8027.2012.00435.x | PMID 23279338 Get It

AbstractMicrovasculature associated with the sciatic nerve was examined using high‐resolution micro‐CT scanning in one group of rats and surgical exploration in another. The results indicate that blood supply to the sciatic nerve is an “open‐ended” system in which the vessels run longitudinally within the epineurium and connect with external vasculature primarily at junction points. Although the range of vasculature found extended down to 4–5 μ, only a few isolated vessels of this size were found, with no capillary “mesh” as such, possibly because of the close proximity of the intrinsic vessel to nerve fibers within the epineurium. While the study did not include direct measurements of flow or nerve function, the “open‐ended” pattern of vasculature found has important implications regarding the relationship between the two. Specifically, the nerve is less vulnerable to a severe or complete disruption in blood supply than it would be under a close‐ended system such as that of the heart or brain, where a severe disruption can occur with the obstruction of only a single vessel. Indeed, the pattern of vasculature found, subject to further study of vasculature at the capillary level, suggests that flow within the intrinsic vessels may be in either direction, depending on circumstances, somewhat like flow within the circle of Willis in the cerebral circulation.
Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates
Linder, Brian J. , Frank, Igor, Umbreit, Eric , Shimko, Mark, Rangel, Laureano J. , Karnes, R. Jeffrey , Fernández, Nicolás , Linder, Brian J

International Journal of Urology | December 22, 2012 | Volume: 20 | Issue: 9 | Pages: 860-864

10.1111/iju.12061 | PMID 23278942 Get It

ObjectivesTo examine the ability of standard and saturation transrectal prostate biopsy techniques to predict appropriate candidates for active surveillance.MethodsBetween 2005 and 2007, 500 consecutive patients underwent transrectal ultrasound‐guided biopsy by a standard template (12 cores) or saturation template (≥18 cores, median 27 cores), with subsequent radical prostatectomy. Using the criteria of Gleason score ≤6, clinical stage T1 or T2a, prostate‐specific antigen <10 and ≤33% of cores involved, 218 patients were potential candidates for active surveillance. Pathology results from the prostatectomy specimens were used to determine the accuracy of each biopsy technique. Biochemical failure after prostatectomy was evaluated using logistic and Cox proportional hazards regression.ResultsA standard biopsy was carried out for 124 patients and saturation biopsy for 94 patients. There was no statistically significant difference between the groups in terms of median age (P = 0.14), preoperative prostate‐specific antigen (P = 0.52) and clinical stage (P = 0.23). Similar rates of Gleason score ≥7 at the time of radical prostatectomy were found, with 14% for standard biopsy and 15% for saturation biopsy (P = 0.70). Upstaging was shown in two standard biopsy patients (1.6%) and no saturation biopsy patients (P = 0.62). A multivariate analysis adjusting for prior prostate biopsy, preoperative prostate‐specific antigen and clinical stage showed no difference in the rate of upgrading based on biopsy technique (P = 0.26). During follow up, 5‐year biochemical failure‐free survival estimates were not significantly different (P = 0.11).ConclusionsIn men with prostate cancer, standard and saturation transrectal prostate biopsies techniques are equally predictive of candidates for active surveillance.
Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high‐risk prostate cancer
Linder, Brian J. , Boorjian, Stephen A. , Umbreit, Eric , Carlson, Rachel E. , Rangel, Laureano J. , Bergstralh, Eric J., Karnes, R. Jeffrey , Linder, Brian J

International Journal of Urology | December 22, 2012 | Volume: 20 | Issue: 8 | Pages: 798-805

10.1111/iju.12047 | PMID 23278850 Get It

BackgroundTo evaluate the impact of adjuvant hormonal therapy after radical prostatectomy on overall survival in high‐risk prostate cancer patients, stratified by comorbidity status.MethodsWe identified 1247 patients who underwent radical prostatectomy from 1988 to 2004 for high‐risk prostate cancer, as defined by National Comprehensive Cancer Network classification. Comorbidity status was stratified by Charlson Comorbidity Index as 0, 1 or >2, as well as by the presence or absence of cardiovascular disease. Overall survival was estimated by the Kaplan–Meier method, and compared within each comorbidity category/adjuvant hormonal therapy strata with the log–rank test.ResultsMedian patient age was 65 years, and the median postoperative follow up was 11.2 years. In total, 419 patients (34%) received adjuvant hormonal therapy. The distribution of Charlson Comorbidity Index was 0, 1 and ≥2 in 861 (69%), 244 (20%) and 142 (11%) patients, respectively. The 10‐year overall survival for patients who received adjuvant hormonal therapy versus those who did not was 75% versus 82% (P = 0.54) for patients with Charlson Comorbidity Index = 0, 72% versus 76% (P = 0.83) with Charlson Comorbidity Index = 1, and 70% versus 68% (P = 0.33) with Charlson Comorbidity Index ≥2. Meanwhile, 155 (12%) patients had cardiovascular disease, and the 10‐year overall survival for patients with cardiovascular disease who received adjuvant hormonal therapy was 72%, compared with 76% without adjuvant hormonal therapy (P = 0.97). On multivariate analysis, receipt of adjuvant hormonal therapy was not associated with non‐prostate cancer mortality (P = 0.24).ConclusionsAdjuvant hormonal therapy after radical prostatectomy for high‐risk prostate cancer does not increase non‐prostate cancer mortality, even among patients with multiple comorbidities. Additional studies are warranted to determine optimal multimodal treatment approach for high‐risk patients.
Evaluation of Fracture Resistance in Aqueous Environment of Four Restorative Systems for Posterior Applications. Part 1
Dhima, Matilda, Assad, Daniel, Volz, John E., An, Kai‐Nan, Berglund, Lawrence J., Carr, Alan B. , Salinas, Thomas

Journal of Prosthodontics | December 22, 2012 | Volume: 22 | Issue: 4 | Pages: 256-260

10.1111/j.1532-849x.2012.00948.x | PMID 23279080 Get It

AbstractPurposeThe goals of this study were to: (1) establish a range of the performance of four restorative systems for posterior single‐tooth crowns under single load to fracture submerged in an aqueous environment, (2) identify restorative system(s) of interest to be examined in the second study phase under sliding contact step‐stress fatigue as full‐contour anatomically appropriate single posterior tooth restoration(s), (3) establish a range for loading/testing for phase 2.Materials and MethodsForty specimens (n = 10/group) of 2 mm uniform thickness were tested. Group 1: monolithic lithium disilicate IPS e.max Press; group 2: IPS e.max ZirPress, 0.8 mm zirconia core with 1.2 mm pressed veneering porcelain; group 3: IPS e.max ZirPress, 0.4 mm zirconia core with 1.6 mm pressed veneering porcelain; group 4: IPS InLine PoM. Specimens were bonded to a block of polycast acrylic resin on a 30° sloped surface with resin cement. Specimens were axially single loaded to failure while submerged under water.ResultsThere was a statistically significant difference (p < 0.001) in failure load among the four restorative systems. Lithium disilicate showed a mean failure load similar to mean maximum posterior bite forces (743.1 ± 114.3 N). IPS e.max Zirpress with a 0.4 mm zirconia core exhibited the lowest mean failure load (371.4 ± 123.0 N).ConclusionFracture resistance of monolithic lithium disilicate in an aqueous environment is promising and requires second phase testing to evaluate the potential of various thicknesses appropriate for posterior single tooth applications. Doubling the IPS e.max Zirpress zirconia core from 0.4 mm to 0.8 mm increased the fracture resistance of this restorative system threefold.